Description: Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus. Biotron Limited is based in North Ryde, Australia.
Home Page: www.biotron.com.au
56 Delhi Road
Sydney,
NSW
2113
Australia
Phone:
61 2 9805 0488
Officers
| Name | Title |
|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD & Executive Director |
| Mr. Peter James Nightingale B.Econ, CA | Company Secretary |
| Dr. Stephen L. Becker M.D. | Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.7785 |
| Price-to-Sales TTM: | 6.0338 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |